Valsamo Anagnostou, MD, PhD

DocwireNews

Valsamo Anagnostou, MD, PhD, of the Johns Hopkins University School of Medicine, discusses advancements in the use of liquid biopsy in lung cancer and her team&rsquo;s research on the topic.&ldquo;We are focusing on the development of liquid biopsy approaches and the implementation of liquid biopsy approaches in clinical cancer care,&rdquo; she said. &ldquo;The field of liquid biopsy is a very exciting field with respect to development of new technologies that allow the very sensitive detection of tumor DNA remnants in the peripheral blood.&rdquo;Dr. Anagnostou explained that her team is &ldquo;working toward the implementation of these exciting technologies in clinical cancer care.&rdquo;&ldquo;We&rsquo;re using these minimally invasive approaches to help us make decisions in terms of how we treat our patients, in terms of how to identify patients with cancer [who] are at higher risk for disease recurrence, how we track tumor burden during therapy, how we monitor a therapeutic response,&rdquo; she said. &ldquo;Certainly, liquid biopsies are now emerging as an exciting opportunity that can be implemented across the clinical cancer care continuum, and it&rsquo;s really exciting to see the clinical validation and the clinical implementation of those approaches.&rdquo;Dr. Anagnostou, who previously published a highly cited article titled &ldquo;<a href="https://aacrjournals.org/cancerdiscovery/article/7/3/264/5907/Evolution-of-Neoantigen-Landscape-during-Immune">Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non&ndash;Small Cell Lung Cancer,&rdquo;</a> spoke about her specific area of research on liquid biopsies and the historic challenges that she hopes to overcome.&ldquo;Our area of focus is tracking response to immunotherapy for patients with advanced cancers, with cancers that are spreading in the body,&rdquo; she said. &ldquo;This has been historically very challenging &hellip; we typically do this by just imaging &hellip; in the context of immunotherapy, we know that these measurements on imaging, they&rsquo;re just inaccurate.&rdquo;It&rsquo;s important to recognize that imaging, which is the &ldquo;gold standard&rdquo; for assessing response to therapy, &ldquo;doesn&rsquo;t capture the unique nature and timing of immunotherapy response,&rdquo; Dr. Anagnostou emphasized. She explained how the liquid biopsy approach may be able to address this issue.&ldquo;What we truly need to do is implement minimally invasive approaches that can very accurately and in real time capture tumor burden and then help us make therapeutic decisions,&rdquo; Dr. Anagnostou said.She also spoke about her recent research on circulating tumor DNA (ctDNA) in non-small cell lung cancer (NSCLC) that she presented during the American Association for Cancer Research (AACR) Annual Meeting 2024.&ldquo;We&rsquo;ve been employing very sensitive approaches &hellip; to actually track mutations in the circulation of patients with cancer and track them over time and then identify specific profiles that may be associated with therapy response, tumor regression and imaging, or tumor expansion and extension on imaging,&rdquo; Dr. Anagnostou said. &ldquo;And what we found is that in the context of immunotherapy, they&rsquo;re actually very distinct profiles with respect to ctDNA&mdash;or circulating tumor DNA&mdash;dynamics that are actually reflective of patients&rsquo; clinical outcomes.&rdquo;She explained the future of this line of research and what could be on the horizon for the use of these liquid biopsy approaches.&ldquo;Certainly, there is extension of these approaches now to the early-stage disease setting &hellip; this is very relevant, as immunotherapy [has] now moved from the metastatic paradigm to the early disease treatment armamentarium, and so we truly, truly need those very sensitive nuanced molecular assays to dissect the clinical responses that that we see with immunotherapy,&rdquo; Dr. Anagnostou concluded.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Dr. Anagnostou on Using Liquid Biopsies to Monitor Reponses to Immunotherapy in NSCLC

Non-Small Cell Lung Cancer

Valsamo Anagnostou, MD, PhD, of the Johns Hopkins University School of Medicine, discusses advancements in the use of liquid biopsy in lung cancer and her team’s research.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe